文献速递肿瘤 PET/CT

18F-FDG与11C-4DST PET/CT评估晚期非小细胞肺癌铂类双药化疗反应的前瞻性研究

18F-FDG and 11C-4DST PET/CT for evaluating response to platinum-based doublet chemotherapy in advanced non-small cell lung cancer: a prospective study.
PubMed 文献 · EJNMMI Res · 2019-01-16

该前瞻性研究纳入22例晚期非小细胞肺癌患者,在基线及2周期铂类双药化疗后行4DST和FDG PET/CT及CT检查,评估代谢参数对无进展生存期和总生存期的预测价值。结果显示基线4DST的MTV预测PFS>4个月的AUC最高(0.73),基线4DST和FDG的MTV均为PFS的显著预测因素,基线4DST的MTV及FDG的MTV和TLG为OS的可能预测因素。

要点

  • 基线4DST MTV预测PFS>4个月的AUC为0.73,阳性预测值80.0%,阴性预测值66.7%,准确率72.7%。
  • 基线FDG MTV和基线4DST MTV对PFS的Kaplan-Meier曲线及log-rank检验结果显著。
  • 基线FDG MTV、基线FDG TLG和基线4DST MTV对OS的Kaplan-Meier曲线及log-rank检验结果显著。

核心结论

  • 基线4DST PET/CT的MTV与基线FDG PET/CT的MTV是有前景的PFS预测因素。
  • 基线4DST PET/CT的MTV以及基线FDG PET/CT的MTV和TLG可能是晚期NSCLC患者OS的预测因素。

研究设计与样本

  • 前瞻性研究,纳入22例病理确诊的晚期非小细胞肺癌患者,计划接受铂类双药化疗。
  • 在基线和2周期铂类双药化疗后(中期)行4DST PET/CT、FDG PET/CT和CT检查。
  • 采用半定量PET参数、RECIST 1.1(基于CT)、EORTC标准及PERCIST 1.0(基于PET/CT)评估疗效。
  • 采用Kaplan-Meier法和log-rank检验比较PFS>4个月与≤4个月患者的基线测量数据及代谢反应,并比较有无代谢反应患者的PFS和OS。

主要发现

  • 在预测PFS>4个月与≤4个月时,基线4DST的MTV在基线测量数据及4DST PET/CT、FDG PET/CT和CT的代谢反应中显示出最高的AUC(0.73)、阳性预测值(80.0%)、阴性预测值(66.7%)和准确率(72.7%)。
  • 基线FDG MTV和基线4DST MTV对PFS的Kaplan-Meier曲线及log-rank检验结果显著。
  • 基线FDG MTV、基线FDG TLG和基线4DST MTV对OS的Kaplan-Meier曲线及log-rank检验结果显著。

关键数值与推荐

  • 基线4DST MTV预测PFS>4个月的AUC为0.73,阳性预测值80.0%,阴性预测值66.7%,准确率72.7%。
  • 采用RECIST 1.1(基于CT)、EORTC标准和PERCIST 1.0(基于PET/CT)进行疗效评估。
  • PFS和OS比较采用Kaplan-Meier统计和log-rank检验。

临床怎么用

  • 在晚期NSCLC患者铂类双药化疗前,可考虑行基线4DST PET/CT和FDG PET/CT测量MTV以辅助预测PFS。
  • 基线4DST MTV以及基线FDG MTV和TLG可能有助于预测OS,但需进一步验证。

局限性

  • 样本量较小(22例),结论需更大规模研究验证。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: 4'-[Methyl-11C] thiothymidine (4DST) PET/CT provides DNA synthesis imaging, which represented a higher correlation with the proliferation in advanced non-small cell lung cancer (NSCLC) than that from imaging with FDG. The aim of this prospective study was to evaluate the potential of 4DST in early therapy monitoring for advanced NSCLC, and to compare the results with those from CT and FDG PET/CT. RESULTS: Patients who had been pathologically diagnosed with advanced NSCLC and were scheduled to receive platinum-doublet chemotherapy (PT-DC) were eligible. PET/CT imaging with 4DST and with FDG, and CT were performed at baseline and after 2 cycles of PT-DC (interim). Patients were evaluated semi-quantitatively after the 2 cycles of PT-DC using several PET parameters, response evaluation criteria in solid tumors (RECIST) 1.1 based on CT measurements, European Organization for Research and Treatment of Cancer (EORTC) criteria and PET Response Criteria in Solid Tumors (PERCIST) 1.0 based on PET/CT measurements. Baseline measurement data and metabolic response were compared between patients with progression-free survival (PFS) > 4 months and ≤ 4 months, and PFS and overall survival (OS) were compared between patients with and without metabolic response measured with each of the different parameters, using Kaplan-Meier statistics and log-rank testing. A total of 22 patients were included in this study. For predicting PFS > 4 months and ≤ 4 months, metabolic tumor volume (MTV) of baseline 4DST showed the highest area under the curve (0.73), positive predictive value (80.0%), negative predictive value (66.7%), and accuracy (72.7%) among baseline measurement data and metabolic responses from 4DST PET/CT, FDG PET/CT, and CT. Kaplan-Meier curves and log-rank tests for PFS with MTV of baseline FDG and baseline 4DST, and for OS with MTV of baseline FDG and baseline TLG, and MTV of baseline 4DST revealed significant results. CONCLUSIONS: MTV of baseline 4DST PET/CT along with MTV of baseline FDG PET/CT represent promising predictors of PFS, and MTV of baseline 4DST PET/CT along with MTV and TLG of baseline FDG PET/CT are possible predictors of OS in patients with advanced NSCLC.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Minamimoto R, Takeda Y, Hotta M, et al. 18F-FDG and 11C-4DST PET/CT for evaluating response to platinum-based doublet chemotherapy in advanced non-small cell lung cancer: a prospective study. EJNMMI Res. 2019. PMID: 30649637. doi:10.1186/s13550-019-0472-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。